Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

This 10.5% Dividend Shines as Americans Get Richer (and Are Less Happy About It)

View original at nasdaq.com
This 10.5% Dividend Shines as Americans Get Richer (and Are Less Happy About It) There's a clear "disconnect" happening in the US economy right now…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CEFs offer access to holdings at a discount to NAV, a deal that does not exist with ETFs

    60% confidence
  • The 60-Paycheck Dividend Plan consists of 5 hand-picked monthly-paying CEFs yielding 9.3% in aggregate, delivering 60 dividend checks per year

    60% confidence
  • USA generates its 10.5% dividend by linking the payout to NAV and committing to distributing approximately 10% of NAV annually; the quarterly payout floats slightly

    60% confidence
  • Default rates in the speculative credit market are falling significantly, most rapidly in the loan market that drove the private-credit panic

    60% confidence
  • Americans are generally getting richer while sentiment is declining simultaneously, creating a paradoxical disconnect

    60% confidence
  • All past major market selloffs including Liberation Day tariffs, the Iran conflict, and the 2022 inflation selloff were buying opportunities, and future pullbacks will be too

    60% confidence
  • American families are less likely to default on debts than in the 2010s and there has been a sharp drop in defaults since early 2025, potentially due to AI-related job opportunities

    60% confidence
  • Current University of Michigan consumer sentiment is at its lowest level in approximately 50 years

    60% confidence
  • The AI buildout is benefiting utilities, energy, infrastructure, construction, transport, retail and other industries, appearing in US companies' bottom lines including riskier firms

    60% confidence
  • Inflation-adjusted worker earnings were flat from 1980 to 2015, then began growing in the late 2010s and have continued to rise, even as consumer sentiment has declined

    60% confidence
  • USA currently trades at an 11.3% discount to NAV, well below its 7.5% one-year average and far below its 0.7% five-year average

    60% confidence
  • S&P 500 firms booked year-over-year earnings gains north of 11% in Q1, the highest since 2022, with sales growth accelerating for years partly due to AI

    60% confidence
  • USA has delivered a 12.3% annualized total return over the last decade consistently

    60% confidence
  • S&P 500 company sales growth has been accelerating for years, in part due to businesses benefiting from the AI boom

    60% confidence
  • The S&P 500 returned 25% in the last year

    60% confidence
  • Liberty All-Star Equity Fund (USA) is a 10.5%-yielding closed-end fund holding large-cap S&P 500 stocks

    60% confidence
  • The S&P 500 averages approximately 10% per year including dividends historically

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · historical avg annual return10 percent
S&P 500 Index Fund · trailing 1yr return25 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com